secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2022-06-03T23:59:59+00:00
Accession:  0001104659-22-068108
Event type: leadership
Sentiment:  negative
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics CFO Thomas Reilly resigns; Richard Makara named interim CFO
-----------------------------------------------------------------------------

- Thomas Reilly resigns as CFO effective June 15, 2022 to pursue a new opportunity.
- Departure is not due to any dispute or disagreement with the company.
- Richard Makara, VP Head of Accounting & Controller, assumes interim CFO role.
- Makara receives 7,500 RSUs vesting at earlier of Dec 31, 2022 or new CFO appointment.
- Makara previously served as interim CFO from Dec 2019 to Oct 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/0001104659-22-068108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465922068108/tm2217665d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-068108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer